Float Short %

10.73

Margin Of Safety %

-15

Put/Call OI Ratio

0.36

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

2.66

Price

262.11

Target Price

317.33

Analyst Recom

Performance Q

27.87

Upside

-8.6%

Beta

0.49

Ticker: KRYS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	KRYS	281.62	0.39	3.75	5057
2026-01-26	KRYS	278.71	0.39	0.67	5065
2026-01-27	KRYS	277.51	0.39	0.50	5069
2026-01-28	KRYS	272.66	0.39	0.16	5075
2026-01-29	KRYS	279.42	0.39	1.00	5073
2026-01-30	KRYS	279.53	0.39	0.42	5073
2026-02-02	KRYS	282.29	0.39	0.02	5076
2026-02-03	KRYS	279.33	0.39	1.09	5110
2026-02-04	KRYS	268.86	0.40	0.19	5161
2026-02-05	KRYS	267.39	0.40	0.08	5203
2026-02-06	KRYS	272.3	0.40	0.08	5197
2026-02-09	KRYS	272.62	0.39	4.83	5217
2026-02-10	KRYS	270.14	0.45	0.40	5471
2026-02-11	KRYS	272.19	0.45	0.03	5505
2026-02-12	KRYS	270.99	0.40	8.83	6040
2026-02-13	KRYS	277.2	0.35	0.31	5858
2026-02-17	KRYS	287.35	0.35	0.38	6008
2026-02-18	KRYS	282.96	0.38	0.06	6504
2026-02-19	KRYS	262.98	0.38	0.21	6534
2026-02-20	KRYS	261.68	0.36	0.93	7391
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	KRYS	281.55	5.0	199.3	6.54
2026-01-26	KRYS	278.76	5.0	206.5	6.54
2026-01-27	KRYS	277.64	5.0	208.9	6.54
2026-01-28	KRYS	272.83	5.0	203.8	6.54
2026-01-29	KRYS	279.34	5.0	220.4	6.54
2026-01-30	KRYS	279.43	5.0	209.8	6.54
2026-02-02	KRYS	282.55	5.0	215.1	6.54
2026-02-03	KRYS	279.42	5.0	206.4	6.54
2026-02-04	KRYS	268.92	5.0	195.1	6.54
2026-02-05	KRYS	267.57	5.0	208.0	6.54
2026-02-06	KRYS	272.48	5.0	218.0	6.54
2026-02-09	KRYS	272.41	5.0	210.6	6.54
2026-02-10	KRYS	270.20	5.0	206.9	6.54
2026-02-11	KRYS	272.55	5.0	213.6	6.54
2026-02-12	KRYS	270.26	5.0	207.4	6.54
2026-02-13	KRYS	277.14	5.0	220.9	6.54
2026-02-17	KRYS	287.89	5.0	226.9	6.54
2026-02-18	KRYS	282.96	5.0	204.3	6.54
2026-02-19	KRYS	262.54	5.0	-	6.54
2026-02-20	KRYS	262.11	15.1	-	7.75
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	KRYS	-2.40	2.81	10.75
2026-01-26	KRYS	-2.40	2.94	10.75
2026-01-27	KRYS	-2.40	2.94	10.75
2026-01-28	KRYS	-2.40	2.94	10.66
2026-01-29	KRYS	-2.40	2.94	10.66
2026-01-30	KRYS	-2.40	2.94	10.66
2026-02-02	KRYS	-2.40	2.87	10.66
2026-02-03	KRYS	-2.40	2.87	10.66
2026-02-04	KRYS	-2.40	2.87	10.66
2026-02-05	KRYS	-2.40	2.87	10.66
2026-02-06	KRYS	-2.40	2.87	10.66
2026-02-09	KRYS	-2.40	2.73	10.66
2026-02-10	KRYS	-2.40	2.73	10.66
2026-02-11	KRYS	-2.40	2.73	10.89
2026-02-12	KRYS	-2.69	2.73	10.89
2026-02-13	KRYS	-2.69	2.73	10.89
2026-02-17	KRYS	-2.69	4.80	10.88
2026-02-18	KRYS	-2.70	4.80	10.88
2026-02-19	KRYS	-2.70	4.80	10.88
2026-02-20	KRYS	-2.68	4.80	10.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.38

Avg. EPS Est. Next Quarter

1.66

Insider Transactions

-2.68

Institutional Transactions

4.8

Beta

0.49

Average Sales Estimate Current Quarter

113

Average Sales Estimate Next Quarter

127

Fair Value

224.01

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

12.1

Max Drawdown 5-Year %

-53.4

Target Price

317.33

P/E

38.25

Forward P/E

25.97

PEG

1.04

P/S

19.67

P/B

6.27

P/Free Cash Flow

40.51

EPS

6.84

Average EPS Est. Cur. Y

7.75

EPS Next Y. (Est.)

10.42

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

52.64

Relative Volume

1.1

Return on Equity vs Sector %

-11.5

Return on Equity vs Industry %

5.9

EPS 1 7Days Diff

-0.6

EPS 1 30Days Diff

-0.69

EBIT Estimation

Krystal Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 295

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today

news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance

stock history KRYS – Krystal Biotech, Inc. invest stock market

stock prices KRYS premarket after hours

ticker KRYS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: KRYS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y